<DOC>
	<DOCNO>NCT02362945</DOCNO>
	<brief_summary>Post-Partum Hemorrhage ( PPH ) common obstetrical complication . It may occur vaginal cesarean delivery report prevalence 4-6 % delivery [ 1 ] . Prophylactic treatment oxytocin fetus extraction common practice . [ 1,2 ] Transexamic acid - Hexakapron potent antifibrinolytic , prevents lysine adhesion plasminogen molecule block bind site . It low fibrinolysis rate reduce bleed [ 9 ] . Systematic treatment anti-fibrinolytic drug surgical practice procedure coronary artery bypass graft , orthopedic surgery liver transplantation [ 10-13 ] . Hexakapron FDA approve drug , define class B drug pregnancy lactation [ 12 ] , already use non-routine fashion delivery room PPH.In obstetrics Hexakapron give vaginal cesarean delivery presume decrease blood loss PPH . 2 study include 453 woman report decrease PPH ( RR 0.51 , 95 % CI 0.36 0.72 ) [ 13-15 ] . However specific protocol prophylactic treatment Hexakapron available oxytocin lacking , research necessary determine guideline [ 16 ] .</brief_summary>
	<brief_title>Hexakaprone Treatment Post-Partum Hemorrhage Prophylactic</brief_title>
	<detailed_description>Post-Partum Hemorrhage ( PPH ) common obstetrical complication . It may occur vaginal cesarean delivery report prevalence 4-6 % delivery [ 1 ] . Prophylactic treatment oxytocin fetus extraction common practice . [ 1,2 ] The increase plasma volume pregnancy , uterine perfusion reach 750ml/min near term [ 3 ] cause excessive blood loss vaginal cesarean delivery . Blood loss approximately 500ml 1000ml vaginal cesarean delivery respectively . Studies show blood transfusion treatment reach 6 % cesarean section [ 5-6 ] . During placental delivery fibrinogen fibrin degradation plasminogen activation occur . This cause fibrinolytic cascade continue 6-10 hour post-partum [ 7 ] . Tissue injury cesarean section may convert hemostatic equilibrium towards fibrinolysis result excessive bleed [ 8 ] / Transexamic acid - Hexakapron potent antifibrinolytic , prevents lysine adhesion plasminogen molecule block bind site . It low fibrinolysis rate reduce bleed [ 9 ] . Systematic treatment anti-fibrinolytic drug surgical practice procedure coronary artery bypass graft , orthopedic surgery liver transplantation [ 10-13 ] . Hexakapron FDA approve drug , define class B drug pregnancy lactation [ 12 ] , already use non-routine fashion delivery room PPH . In obstetrics Hexakapron give vaginal cesarean delivery presume decrease blood loss PPH . 2 study include 453 woman report decrease PPH ( RR 0.51 , 95 % CI 0.36 0.72 ) [ 13-15 ] . However specific protocol prophylactic treatment Hexakapron available oxytocin lacking , research necessary determine guideline [ 16 ] . PPH jeopardize young reproductive woman 's health , specifically related major morbidity context prior anemia feature population high rate [ 17 ] . PPH major maternal cause death , 100000 case per year [ 6 ] . Thus investigator seek investigate efficacy Hexakapron , prophylactic treatment vaginal delivery cesarean section , reduce PPH .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Postpartum Hemorrhage</mesh_term>
	<mesh_term>Oxytocin</mesh_term>
	<criteria>Normal vaginal delivery . Operative vaginal delivery ( Vaccum Forceps ) . Elective cesarean section . Age 1850 . Excessive pain ( VAS &gt; 4 ) . Blood clot disturbance major hematologic disease . Suspected PlacentaPrevia . Multiple gestation . Contraindications Hexakapron treatment : Atrial fibrillation . Coronary artery stenting . CABG ( coronary artery bypass graft ) past year . Hematuria ( prior pregnancy ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>